ARCHIVES

Experts Say Interpretable Results Unlikely In Burzynski’s Antineoplastons Studies

This article is from The Cancer Letter archive.

Vol. 24 No. 36 | September 25, 1998

Download PDF Visit The Full Archive

Related Articles

NCI Programs: Genetic Variations Discovered, Added to NCI Database

June 11, 1999

Two Second-Line CML Drugs Work Front-Line, Studies Find

January 29, 2010

ODAC Finds Increase In Progression-Free Survival Unconvincing To Approve sNDA For Gemzar In Advanced Ovarian Cancer.

March 24, 2006

Drug Bills Cut $500 Million From Cancer Care, ASCO Says.

July 4, 2003

FDA to refer false statements by regulated companies to SEC.

February 27, 2004

High Dose Chemotherapy Significantly Prolongs Survival In ECOG Clinical Trial

November 28, 2008